Loading clinical trials...
Loading clinical trials...
Immunomodulatory Effect of Pleuran (β-glucan From Pleurotus Ostreatus) in Children With Recurrent Respiratory Tract Infections
International, multicentre, prospective, randomized, double-blind, placebo-controlled study with a food supplement Imunoglukan P4H® chewable tablets to evaluate preventive effect on reduction of respiratory tract infections (RTIs) in children with a history of recurrent respiratory tract infections (RRTIs) in the previous infectious season prior enrolment. Participants or their guardians will record the incidence and duration of RTIs in the Patient diary for 3 months.
Study population: Children aged 3-18 years with a history of RRTIs: * Age 3 to 5 years (\< 6 years): 6 or more upper or lower respiratory tract infections from October 2022 until the end of March 2023 * Age 6 to 18 years (≥ 6 years): 3 or more upper or lower respiratory tract infections from October 2022 until the end of March 2023 Study design: International (Slovak republic, Czech republic, Serbia), multicentre (36), prospective, randomized, double-blind, placebo-controlled study Primary endpoint: To evaluate the effect of Imunoglukan P4H® chewable tablets (IMG®+ zinc+ vitamin D3) compared to the placebo group (zinc + vitamin D3) on: • reduction in the number of RTIs episodes (total number) Secondary endpoints: To evaluate the effect of Imunoglukan P4H® chewable tablets (IMG®+ zinc+ vitamin D3) compared to the placebo group (zinc + vitamin D3) on: * reduction in the number of episodes of RTI subtypes * reduction in the duration of RTI episodes (total duration, RTI subtypes) * reduction of the need for antibiotic (ATB) therapy * reduction of the number of missed days at school/nursery due to RTI * reduction of the number of missed working days due to RTIs * reduction of the number of emergency department visits due to RTI * reduction of the number of physician visits due to RTI * tolerability and safety Randomization: * Active group: Imunoglukan P4H® chewable tablets (IMG® 50 mg + Zinc 5 mg + Vitamin D3 10 μg in 1 tablet): * Placebo group: Placebo chewable tablets (Zinc 5 mg + Vitamin D 10 μg in 1 tablet) Dosage: * up to 25 kg of body weight 1 tablet once a day for 3 months * over 25 kg 2 tablets once a day for 3 months Diagnostic procedures: • Patient diary (Incidence and duration of RTIs)
Age
3 - 18 years
Sex
ALL
Healthy Volunteers
No
IMUNOGLUKAN CZ, s.r.o.
Prague, Czechia
Medis Pharma d.o.o. Beograd
Belgrade, Serbia
Imunoglukan, s.r.o.
Bratislava, Slovakia
Start Date
September 25, 2023
Primary Completion Date
March 31, 2024
Completion Date
March 31, 2024
Last Updated
May 16, 2025
217
ACTUAL participants
Imunoglukan P4H® chewable tablets
DIETARY_SUPPLEMENT
Placebo chewable tablets
DIETARY_SUPPLEMENT
Lead Sponsor
Pleuran, s.r.o.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions